UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 29, 2010
PDL BioPharma, Inc.
(Exact name of Company as specified in its charter)
000-19756
(Commission File Number)
| Delaware | 94-3023969 | |
| (State or Other Jurisdiction of Incorporation) |
(I.R.S. Employer Identification No.) |
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)
(775) 832-8500
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On April 29, 2010, PDL BioPharma, Inc. (the “Company”) issued a press release announcing the financial results for the first quarter ended March 31, 2010. A copy of this earnings release is attached as Exhibit 99.1 hereto. The Company will host an earnings call and webcast on April 29, 2010 in which its financial results for the first quarter ended March 31, 2010 will be discussed.
Limitation of Incorporation by Reference
In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibit, is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Cautionary Statements
This filing includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2009 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2010. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated April 29, 2010, regarding the financial results of PDL BioPharma, Inc. for the first quarter ended March 31, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PDL BIOPHARMA, INC. | ||
| (Company) | ||
| By: | /s/ Christine R. Larson | |
| Christine R. Larson | ||
| Vice President and Chief Financial Officer | ||
Dated: April 29, 2010
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated April 29, 2010, regarding the financial results of PDL BioPharma, Inc. for the first quarter ended March 31, 2010 |
Exhibit 99.1
| Contacts: |
||
| Cris Larson PDL BioPharma, Inc. 775-832-8505 Cris.Larson@pdl.com |
Danielle Bertrand WCG 415-946-1056 dbertrand@wcgworld.com | |
PDL BioPharma Announces First Quarter 2010 Financial Results
– Conference Call Today at 4:30 p.m. Eastern Time –
INCLINE VILLAGE, NV, April 29, 2010 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2010.
Total revenues for the first quarter of 2010 were $62.1 million, compared with $62.6 million for the same period of 2009. Due to ongoing legal disputes with MedImmune, first quarter 2010 revenue does not include royalties on sales of Synagis. Excluding MedImmune, first quarter 2010 revenue grew by more than 35 percent over the first quarter of 2009. The growth was primarily driven by increased fourth quarter 2009 sales by our licensees of Avastin® and Herceptin®, which are marketed by Genentech and Roche, Lucentis®, which is marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. PDL received royalties for these product sales in the first quarter of 2010.
Total general and administrative expenses for the first quarter of 2010 were $9.4 million, compared with $4.7 million for the same period of 2009. The increase was primarily driven by increased legal expense. Significant expense items in the first quarter of 2010 were legal fees of $6.4 million, compensation and benefits of $1.0 million, professional service fees of $1.1 million, and stock-based compensation expense of $0.2 million.
Net income for the first quarter of 2010 was $26.0 million, or $0.15 per diluted share, compared with net income of $37.5 million, or $0.23 per diluted share, for the same period in 2009.
Net cash provided by operating activities for the first quarter of 2010 was $26.9 million, compared with $27.7 million for the first quarter of 2009. At March 31, 2010, PDL had cash and cash equivalents of $319.7 million, compared with $303.2 million at December 31, 2009.
During April 2010, PDL repurchased an aggregate of $77.2 million in principal of its convertible notes due in August 2023. This repurchase represents a reduction in our fully diluted shares outstanding of approximately 13.7 million shares.
2010 Dividends
PDL previously announced that it would pay two special dividends of $0.50 per share each, to its stockholders in 2010. The first special dividend, totaling $59.8 million, was paid on April 1, 2010 to all stockholders of record on March 15, 2010. The second special dividend will be paid on October 1, 2010 to all stockholders of record on September 15, 2010. PDL does not pay regular dividends.
Second Quarter 2010 Revenue Guidance
As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. Second quarter 2010 revenue guidance will be provided in early of June.
Conference Call Details
PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, April 29.
To access the live conference call via phone, please dial (800) 688-0836 from the United States and Canada or (617) 614-4072 internationally. The conference ID is 10899707. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through April 30, 2010, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 55966470.
To access the live and subsequently archived webcast of the conference call, go to the company’s website at http://www.pdl.com and go to “Company Presentations & Events.” Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Forward-looking Statements
This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:
| • | The expected rate of growth in royalty-bearing product sales by PDL’s existing licensees; |
| • | The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.; |
| • | The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful; |
| • | Changes in any of the other assumptions on which PDL’s projected royalty revenues are based; |
| • | The outcome of pending litigation or disputes; and |
| • | The failure of licensees to comply with existing license agreements, including any failure to pay royalties due. |
Other factors that may cause PDL’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL’s filings with the SEC, including the “Risk Factors” sections of its annual and quarterly reports filed with the SEC. Copies of PDL’s filings with the SEC may be obtained at the “Investors” section of PDL’s website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME DATA
(Unaudited)
(In thousands, except per share amounts)
| Quarter
Ended March 31, |
||||||||
| 2010 | 2009 | |||||||
| Revenues |
||||||||
| Royalties |
$ | 62,061 | $ | 62,298 | ||||
| License and other |
— | 324 | ||||||
| Total revenues |
62,061 | 62,622 | ||||||
| General and administrative expenses |
9,410 | 4,693 | ||||||
| Operating income |
52,651 | 57,929 | ||||||
| Interest and other income, net |
80 | 336 | ||||||
| Interest expense |
(12,527 | ) | (3,574 | ) | ||||
| Income before income taxes |
40,204 | 54,691 | ||||||
| Income tax expense |
14,197 | 17,234 | ||||||
| Net income |
$ | 26,007 | $ | 37,457 | ||||
| Net income per basic share |
$ | 0.22 | $ | 0.31 | ||||
| Net income per diluted share |
$ | 0.15 | $ | 0.23 | ||||
| Cash dividends declared and paid per common share |
$ | 1.00 | $ | 1.00 | ||||
| Shares used to compute income per basic share |
119,525 | 119,327 | ||||||
| Shares used to compute income per diluted share |
184,308 | 172,570 | ||||||
PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
(In thousands)
| March 31, 2010 |
December 31, 2009 |
|||||||
| Cash and cash equivalents |
$ | 319,674 | $ | 303,227 | ||||
| Total assets |
$ | 358,251 | $ | 338,411 | ||||
| Convertible notes payable |
$ | 427,978 | $ | 427,998 | ||||
| Non-recourse notes payable |
$ | 287,379 | $ | 300,000 | ||||
| Total stockholders’ deficit |
$ | (501,059 | ) | $ | (415,953 | ) | ||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA | ||||||||
| (Unaudited) | ||||||||
| (In thousands) | ||||||||
| Quarter Ended March 31, |
||||||||
| 2010 | 2009 | |||||||
| Net income |
$ | 26,007 | $ | 37,457 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities |
2,653 | 27 | ||||||
| Changes in assets and liabilities |
(1,724 | ) | (9,771 | ) | ||||
| Net cash provided by operating activities |
$ | 26,936 | $ | 27,713 | ||||
MIX OF U.S.-BASED SALES AND EX-U.S.-BASED MANUFACTURING AND SALES OF
GENENTECH PRODUCTS
(Unaudited)
| Quarter Ended March 31, |
||||||
| 2010 | 2009 | |||||
| Mix of Genentech products: |
||||||
| U.S.-based Sales |
81 | % | 93 | % | ||
| Ex-U.S.-based Manufacturing and Sales |
19 | % | 7 | % | ||
| The information in the table above is based on information provided to us by Genentech. |
| |||||